Liposomal Doxorubicin and Carboplatin in Treating Patients With Gynecologic Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically or cytologically confirmed fallopian tube cancer, Muellerian mixed tumor, endometrial cancer, uterine sarcoma, ovarian cancer with sarcoma parts, or cervical cancer
• •* No ovarian epithelial cancer
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 and over
• •Performance status:
• •ECOG 0-2 OR
• •Karnofsky 70-100%
• •Life expectancy:
• •At least 3 months
• •Hematopoietic:
• •Absolute neutrophil count at least 1,500/mm3
• •Platelet count at least 100,000/mm3
• •Hemoglobin greater than 10.0 g/dL
• •Hepatic:
• •Bilirubin no greater than 1.25 times upper limit of normal
• •Renal:
• •Glomerular filtration rate at least 60 mL/min
• •Cardiovascular:
• •No atrial or ventricular arrhythmias
• •No congestive heart failure even if stabilized on medication
• •No New York Heart Association class III or IV heart disease
• •No myocardial infarction within the past 6 months
• •Other:
• •No pre-existing sensory or motor neuropathy grade 2 or greater
• •No active infection
• •No other serious medical condition that would preclude study
• •Not pregnant
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •At least 4 weeks since prior immunotherapy
• •Chemotherapy:
• •No more than 1 prior chemotherapy regimen for the malignancy
• •No other concurrent chemotherapy
• •Endocrine therapy:
• •Prior hormonal therapy within the past 10 days allowed
• •No concurrent hormonal therapy
• •Radiotherapy:
• •At least 6 weeks since prior radiotherapy to no more than 25% of bone marrow
• •Surgery:
• •Not specified
• •Other:
• •At least 30 days since prior experimental agents
• •No other concurrent therapies that would preclude study
• •No concurrent participation in another study